Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
Publication
, Journal Article
Hershfield, MS; Callaghan, JT; Tassaneeyakul, W; Mushiroda, T; Thorn, CF; Klein, TE; Lee, MTM
Published in: Clin Pharmacol Ther
February 2013
Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B*58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer-reviewed guidelines for allopurinol use based on HLA-B genotype.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
February 2013
Volume
93
Issue
2
Start / End Page
153 / 158
Location
United States
Related Subject Headings
- Stevens-Johnson Syndrome
- Pharmacology & Pharmacy
- Pharmacogenetics
- Hyperuricemia
- Humans
- HLA-B Antigens
- Gout Suppressants
- Gout
- Genotype
- Dose-Response Relationship, Drug
Citation
APA
Chicago
ICMJE
MLA
NLM
Hershfield, M. S., Callaghan, J. T., Tassaneeyakul, W., Mushiroda, T., Thorn, C. F., Klein, T. E., & Lee, M. T. M. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther, 93(2), 153–158. https://doi.org/10.1038/clpt.2012.209
Hershfield, M. S., J. T. Callaghan, W. Tassaneeyakul, T. Mushiroda, C. F. Thorn, T. E. Klein, and M. T. M. Lee. “Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.” Clin Pharmacol Ther 93, no. 2 (February 2013): 153–58. https://doi.org/10.1038/clpt.2012.209.
Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013 Feb;93(2):153–8.
Hershfield, M. S., et al. “Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.” Clin Pharmacol Ther, vol. 93, no. 2, Feb. 2013, pp. 153–58. Pubmed, doi:10.1038/clpt.2012.209.
Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MTM. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013 Feb;93(2):153–158.
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
February 2013
Volume
93
Issue
2
Start / End Page
153 / 158
Location
United States
Related Subject Headings
- Stevens-Johnson Syndrome
- Pharmacology & Pharmacy
- Pharmacogenetics
- Hyperuricemia
- Humans
- HLA-B Antigens
- Gout Suppressants
- Gout
- Genotype
- Dose-Response Relationship, Drug